A Phase 2 interventional study of Beclomethasone dipropionate HFA Nasal Aerosol and Placebo in Seasonal Allergic Rhinitis and Hayfever, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 26 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2012-05-22.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 107 studies in Rhinitis, Allergic, Seasonal with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Rhinitis, Allergic, Seasonal · United States.
Among the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States, this one is the 48th largest by enrollment of the 101 interventional ones that give a count, is one of 13 that started in 2009, is one of 20 in phase 2, and was the 54th registered.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →1 of the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States is open now. Recruiting first, the newest first:
Polyrizon Ltd. · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 24 · Phase 3 48 · Phase 4 18
First in 2001; this study’s year is marked. 13 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 487 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Median enrollment 446 across the 101 interventional studies, 92 across the 5 observational. Of the 100 that completed or were terminated, 56 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
86 of 107 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 8 studies filed under Rhinitis, Allergic, Seasonal — fewer than ten, so there is no comparison to draw.
1 of the studies in Rhinitis, Allergic, Seasonal with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07588672Polyrizon Ltd.Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis | 2027-07-15 |
Add it to your calendar (.ics) → With an account.
Among the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2, randomized, double-blind, placebo-controlled, parallel-group, 2-week, multi-center, dose-range-finding study in male or female patients (12 years and older) with SAR.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the 2-week double-blind Treatment Period participants self-administered two actuations (one per nostril) of 40 micrograms (µg) BDP HFA and two actuations of placebo HFA once daily.
Drug: Beclomethasone dipropionate HFA Nasal Aerosol · Drug: Placebo
During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of 40 µg BDP HFA once daily.
Drug: Beclomethasone dipropionate HFA Nasal Aerosol
During the 2-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily.
Drug: Beclomethasone dipropionate HFA Nasal Aerosol
During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily.
Drug: Placebo
Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
Also known as: QNASL(TM)
HFA Vehicle Aerosol
Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period
Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the past 12 hours twice daily (AM \& PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.
Time frame: Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)
Change From Baseline in Average AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two Week Treatment Period
Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the 10 minutes prior to the assessment, twice daily (AM \& PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of symptom, bothersome but tolerable); 3=severe (symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.
Time frame: Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)
Change From Baseline in Morning Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two-week Treatment Period
Change from Baseline in the morning patient-reported instantaneous TNSS. Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the past 10 minutes (prior to the assessment) in the morning on a scale from 0 (mild symptoms) to 3 (severe symptoms). The total nasal symptom score (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.
Time frame: Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)
Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7. A negative change from Baseline score indicates symptom improvement.
Time frame: Baseline and Week 2
Change From Baseline in Morning 24-hour Reflective Ocular Symptom Score Over the Two-week Treatment Period
Participants recorded the severity of their symptoms (itching/burning eyes, tearing/watering eyes and redness of eyes) for the past 24 hours each morning using the following scale: 0=absent (no sign/symptoms); 1=mild (sign/symptom present, minimal awareness, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptom hard to tolerate, interfere with daily activities or sleeping). The total ocular symptom score (sum of 3 symptom scores) ranges from 0 to 9 (worst symptoms). A negative change from Baseline score indicates symptom improvement.
Time frame: Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)
Change From Baseline in Morning 24-hour Reflective Non-nasal Symptom Score Over the Two-week Treatment Period
Participants recorded the severity of their symptoms (itching/burning eyes, tearing/watering eyes, redness of eyes and itching of ears or palate) for the past 24 hours each morning using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (symptoms hard to tolerate, interfere with daily activities or sleeping). Total non-nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.
Time frame: Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)
A total of 685 patients were screened and 635 were enrolled in the study and participated in the Run-in Period. Of the 635 enrolled patients, 487 were randomized to treatment. The study was performed in the spring during tree and grass pollen seasons.
| Milestone | BDP HFA 80 µg/Day | BDP HFA 160 µg/Day | BDP HFA 320 µg/Day | Placebo |
|---|---|---|---|---|
| Started | 118 | 123 | 122 | 124 |
| Intent to treat / safety population | 118 | 123 | 122 | 123 |
| Completed | 116 | 120 | 120 | 114 |
| Not completed | 2 | 3 | 2 | 10 |
| Withdrew: Adverse event | 0 | 1 | 2 | 6 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 1 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 3 |
Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the past 12 hours twice daily (AM \& PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.
| units on a scale | BDP HFA 80 µg/Day | BDP HFA 160 µg/Day | BDP HFA 320 µg/Day | Placebo |
|---|---|---|---|---|
| Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period | -1.88 ± 0.18 | -1.87 ± 0.18 | -2.22 ± 0.18 | -1.59 ± 0.18 |
Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the 10 minutes prior to the assessment, twice daily (AM \& PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of symptom, bothersome but tolerable); 3=severe (symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.
| units on a scale | BDP HFA 80 µg/Day | BDP HFA 160 µg/Day | BDP HFA 320 µg/Day | Placebo |
|---|---|---|---|---|
| Change From Baseline in Average AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two Week Treatment Period | -1.77 ± 0.18 | -1.71 ± 0.18 | -2.10 ± 0.18 | -1.50 ± 0.18 |
Change from Baseline in the morning patient-reported instantaneous TNSS. Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the past 10 minutes (prior to the assessment) in the morning on a scale from 0 (mild symptoms) to 3 (severe symptoms). The total nasal symptom score (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.
| units on a scale | BDP HFA 80 µg/Day | BDP HFA 160 µg/Day | BDP HFA 320 µg/Day | Placebo |
|---|---|---|---|---|
| Change From Baseline in Morning Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two-week Treatment Period | -1.76 ± 0.18 | -1.71 ± 0.18 | -2.14 ± 0.18 | -1.31 ± 0.18 |
The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7. A negative change from Baseline score indicates symptom improvement.
| units on a scale | BDP HFA 80 µg/Day | BDP HFA 160 µg/Day | BDP HFA 320 µg/Day | Placebo |
|---|---|---|---|---|
| Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) | -1.30 ± 0.17 | -1.33 ± 0.15 | -1.62 ± 0.17 | -1.22 ± 0.16 |
Participants recorded the severity of their symptoms (itching/burning eyes, tearing/watering eyes and redness of eyes) for the past 24 hours each morning using the following scale: 0=absent (no sign/symptoms); 1=mild (sign/symptom present, minimal awareness, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptom hard to tolerate, interfere with daily activities or sleeping). The total ocular symptom score (sum of 3 symptom scores) ranges from 0 to 9 (worst symptoms). A negative change from Baseline score indicates symptom improvement.
| units on a scale | BDP HFA 80 µg/Day | BDP HFA 160 µg/Day | BDP HFA 320 µg/Day | Placebo |
|---|---|---|---|---|
| Change From Baseline in Morning 24-hour Reflective Ocular Symptom Score Over the Two-week Treatment Period | -1.16 ± 0.16 | -1.11 ± 0.16 | -1.46 ± 0.16 | -1.17 ± 0.16 |
Participants recorded the severity of their symptoms (itching/burning eyes, tearing/watering eyes, redness of eyes and itching of ears or palate) for the past 24 hours each morning using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (symptoms hard to tolerate, interfere with daily activities or sleeping). Total non-nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.
| units on a scale | BDP HFA 80 µg/Day | BDP HFA 160 µg/Day | BDP HFA 320 µg/Day | Placebo |
|---|---|---|---|---|
| Change From Baseline in Morning 24-hour Reflective Non-nasal Symptom Score Over the Two-week Treatment Period | -1.55 ± 0.22 | -1.49 ± 0.22 | -1.91 ± 0.21 | -1.51 ± 0.22 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BDP HFA 80 µg/Day | — | 0/118 (0%) | 6/118 (5.1%) |
| BDP HFA 160 µg/Day | — | 2/123 (1.6%) | 3/123 (2.4%) |
| BDP HFA 320 µg/Day | — | 0/122 (0%) | 3/122 (2.5%) |
| Placebo | — | 0/123 (0%) | 1/123 (0.8%) |
| Event | BDP HFA 80 µg/Day | BDP HFA 160 µg/Day | BDP HFA 320 µg/Day | Placebo |
|---|---|---|---|---|
| AngioedemaSkin and subcutaneous tissue disorders | 0/118 | 1/123 | 0/122 | 0/123 |
| Abortion spontaneous incompletePregnancy, puerperium and perinatal conditions | 0/118 | 1/123 | 0/122 | 0/123 |
| Event | BDP HFA 80 µg/Day | BDP HFA 160 µg/Day | BDP HFA 320 µg/Day | Placebo |
|---|---|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 6/118 | 3/123 | 3/122 | 1/123 |
| Age Continuous(years) | BDP HFA 80 µg/Day | BDP HFA 160 µg/Day | BDP HFA 320 µg/Day | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 37.6 ± 13.86 | 39.8 ± 15.26 | 38.5 ± 14.74 | 38.2 ± 13.95 | 38.5 ± 14.45 |
| Sex: Female, Male(Participants) | BDP HFA 80 µg/Day | BDP HFA 160 µg/Day | BDP HFA 320 µg/Day | Placebo | Total |
|---|---|---|---|---|---|
| Female | 76 | 86 | 81 | 73 | 316 |
| Male | 42 | 37 | 41 | 50 | 170 |
| Race/Ethnicity, Customized(Participants) | BDP HFA 80 µg/Day | BDP HFA 160 µg/Day | BDP HFA 320 µg/Day | Placebo | Total |
|---|---|---|---|---|---|
| White | 92 | 99 | 98 | 97 | 386 |
| Black | 23 | 18 | 22 | 19 | 82 |
| Asian | 2 | 5 | 0 | 6 | 13 |
| Other | 1 | 1 | 2 | 1 | 5 |
| Race/Ethnicity, Customized(participants) | BDP HFA 80 µg/Day | BDP HFA 160 µg/Day | BDP HFA 320 µg/Day | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 14 | 10 | 17 | 15 | 56 |
| Not Hispanic or Latino | 104 | 113 | 105 | 108 | 430 |
| Region of Enrollment(participants) | BDP HFA 80 µg/Day | BDP HFA 160 µg/Day | BDP HFA 320 µg/Day | Placebo | Total |
|---|---|---|---|---|---|
| United States | 118 | 123 | 122 | 123 | 486 |
The record gives a start of Mar 2009, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 3 years after primary completion. A results delay was requested in Aug 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Beclomethasone
Rhinitis, Allergic, Seasonal →
Teva Branded Pharmaceutical Products R&D, Inc. →